Tromethamine

Tromethamine

SCHEMBL3473649

CC(=O)O.CC(=O)O.CC(=O)O.CC(=O)O.NC(CO)(CO)CO.NCCN

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA

The experimentally established mechanism targets of Tromethamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.53
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
FFAR3 O14843 1/20 0.37
LCK P06239 1/20 0.37
FYN P06241 1/20 0.37
GABRR1 P24046 3/20 0.32
PAOX Q6QHF9 1/20 0.32
GLRA1 P23415 1/20 0.32
SLC6A9 P48067 1/20 0.32
OR51E2 Q9H255 1/20 0.32
ODC1 P11926 2/20 0.31
KDM4E B2RXH2 1/20 0.31
S1PR1 P21453 1/20 0.31
GABRR3 A8MPY1 1/20 0.31
GABRP O00591 1/20 0.31
GABRD O14764 1/20 0.31
HDAC3 O15379 1/20 0.31
GABBR2 O75899 1/20 0.31
CYP1A2 P05177 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tromethamine SCHEMBL29111702 0.97 LMNA (0.50) LMNAKMT2AMEN1FFAR3LCK
Tromethamine SCHEMBL7347818 0.92 LMNA (0.62) LMNAKMT2AMEN1FFAR3LCK
Tromethamine SCHEMBL194002 0.92 LMNA (0.62) LMNAKMT2AMEN1FFAR3LCK
Tromethamine SCHEMBL4581519 0.92 LMNA (0.62) LMNAKMT2AMEN1FFAR3LCK
Tromethamine SCHEMBL5891164 0.84 MEN1 (0.53) LMNAKMT2AMEN1FFAR3LCK
Acetic Acid SCHEMBL9509800 0.84 MEN1 (0.45) LMNAKMT2AMEN1FFAR3LCK
Tromethamine SCHEMBL5710709 0.83 LMNA (0.67) LMNAKMT2AMEN1S1PR1BLM
Tromethamine SCHEMBL3761763 0.83 MEN1 (0.77) LMNAKMT2AMEN1KDM4ETSHR
Acetic Acid SCHEMBL27666617 0.83 FFAR3 (0.54) LMNAKMT2AMEN1FFAR3LCK
Acetic Acid SCHEMBL5150444 0.80 FFAR3 (0.44) LMNAKMT2AMEN1FFAR3LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116926971-B Antigen fibrillation composition and application thereof in lyocell fabric 广东德美精细化工集团股份有限公司 2024-07-12 CN claimed
CN-117090052-A Preparation method of antigen fibrillated lyocell fibers 广东德美精细化工集团股份有限公司 2023-11-21 CN claimed
CN-116926971-A Antigen fibrillation composition and application thereof in lyocell fabric 广东德美精细化工集团股份有限公司 2023-10-24 CN claimed
CN-116323968-A Decrosslinking compounds for spatial analysis and methods of use 10X基因组学有限公司 2023-06-23 CN claimed
CN-110964636-A Automatic nucleic acid magnetic bead purification micro-fluidic chip based on laminar flow 东南大学 2020-04-07 CN claimed
CN-116926971-B Antigen fibrillation composition and application thereof in lyocell fabric 广东德美精细化工集团股份有限公司 2024-07-12 CN disclosed
CN-118146257-A Phosphatidylamide compound containing multiple tertiary amino structures, composition and application thereof 北京大学 2024-06-07 CN disclosed
CN-118146262-A Bi-phosphatidyl amide compound containing multiple tertiary amino structures, composition and application thereof 北京大学 2024-06-07 CN disclosed
CN-112439079-B Preparation of medicine-carrying cage-shaped protein by organic solvent method 昆山新蕴达生物科技有限公司 2024-04-12 CN disclosed
CN-117090052-A Preparation method of antigen fibrillated lyocell fibers 广东德美精细化工集团股份有限公司 2023-11-21 CN disclosed
CN-116926971-A Antigen fibrillation composition and application thereof in lyocell fabric 广东德美精细化工集团股份有限公司 2023-10-24 CN disclosed
CN-116323968-A Decrosslinking compounds for spatial analysis and methods of use 10X基因组学有限公司 2023-06-23 CN disclosed
WO-2009035739-A2 UNIVERSAL MATRIX NORTHWESTERN UNIVERSITY (US) 2009-03-19 WO disclosed
EP-0669986-B1 FULLY IMPAIRED CONSENSUS KOZAC SEQUENCES FOR MAMMALIAN EXPRESSION IDEC PHARMA CORP (US) 2003-04-09 EP disclosed
US-20030036113-A1 Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same BIOGEN IDEC INC. 2003-02-20 US disclosed
US-6159730-A Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same IDEC PHARMACEUTICAL CORPORATION (US) 2000-12-12 US disclosed
US-6017733-A TRANFORMING MAMMALIAN CELLS WITH AN EXPRESSION VECTOR THAT CONTAINS A FULLY IMPAIRED CONSENSUS KOZAK SEQUENCE AND A GENE ENCODED A TARGET DNA WITHIN THE INSERTION REGION; INCREASE EXPRESSION EFFICIENCY OF THE GENE PRODUCT OF INTEREST IDEC PHARMACEUTICALS CORPORATION (US) 2000-01-25 US disclosed
WO-1998016540-A1 IMPROVED COUPLING ACTIVATORS FOR OLIGONUCLEOTIDE SYNTHESIS PROLIGO LLC (US) 1998-04-23 WO disclosed
US-5733779-A GENETIC ENGINEERING IDEC PHARMACEUTICALS CORPORATION (US) 1998-03-31 US disclosed
US-5648267-A Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same IDEC PHARMACEUTICALS CORPORATION (US) 1997-07-15 US disclosed